Branka M.
- Country
- Croatia
- Department
- Immunodermatology
Research Overview
- A double-blind, randomized, placebo-controlled, interventional, multicenter, phase III clinical trial to investigate the safety and efficacy of ABCB5-positive mesenchymal stromal cells (ABCB5+ MSCs) on epidermolysis bullosa (EB)
- Efficacy and Safety Evaluation of Efgartigimod PH20 SC in Adults with Bullous Pemphigoid: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study
- Phase IB Open-Label Extension Basket Trial of RAY121 in Classical Complement Pathway Inhibition for Various Immunological Diseases
Data & Insights
Has run more than one trial at 41 of 87 partner sites.
Specializations
Dermatological Conditions
This investigator specializes in treating severe epidermolysis bullosa variants, including recessive dystrophic epidermolysis bullosa (RDEB) and junctional epidermolysis bullosa (JEB). Their research extends to bullous pemphigoid, a chronic autoimmune blistering condition.
- Genetic Skin Disorders
- Autoimmune Blistering Diseases
- Advanced Wound Care
Autoimmune Disorders
The investigator focuses on various autoimmune conditions, including immune thrombocytopenia and dermatomyositis. Their work encompasses the study of immune-mediated necrotizing myopathy and its treatments.
- Inflammatory Muscle Disorders
- Blood Platelet Disorders
- Complement Pathway Disorders
Systemic Conditions
Their expertise extends to complex systemic disorders including Behçet's Syndrome and antiphospholipid syndrome. The research focuses on innovative therapeutic approaches targeting the classical complement pathway.
- Vascular Inflammation
- Autoimmune Vasculitis
- Complement System Modulation
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.